Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro

doi:10.3748/wjg.v11.i17.2643

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2424)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

226

HTML

1903

Figures (1-6)

174

Tables (1-2)

121

Sum=2424

May 7, 2005 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. May 7, 2005; 11(17): 2643-2646
Published online May 7, 2005. doi: 10.3748/wjg.v11.i17.2643

Full Size Figure Download Figure

Figure 5 Results of flow cytometry analysis of HepA cells treated with Fu-GCL for 48 h and DNA content was determined by flow cytometry (mean±SD, n = 5). A: control; B: 5-Fu-GCL; C: free 5-Fu; D: apoptosis percentage of HepA cells treated with Fu-GCL. ^aP<0.05 vs 5-F-Fu.

Citation: Jin Y, Li J, Rong LF, Li YH, Guo L, Xu SY. Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro. World J Gastroenterol 2005; 11(17): 2643-2646
URL: https://www.wjgnet.com/1007-9327/full/v11/i17/2643.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i17.2643